Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
Simon A. Jones, … , Jürgen Scheller, Stefan Rose-John
Simon A. Jones, … , Jürgen Scheller, Stefan Rose-John
Published September 1, 2011
Citation Information: J Clin Invest. 2011;121(9):3375-3383. https://doi.org/10.1172/JCI57158.
View: Text | PDF
Science in Medicine Article has an altmetric score of 23

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

  • Text
  • PDF
Abstract

The successful treatment of certain autoimmune conditions with the humanized anti–IL-6 receptor (IL-6R) antibody tocilizumab has emphasized the clinical importance of cytokines that signal through the β-receptor subunit glycoprotein 130 (gp130). In this Review, we explore how gp130 signaling controls disease progression and examine why IL-6 has a special role among these cytokines as an inflammatory regulator. Attention will be given to the role of the soluble IL-6R, and we will provide a perspective into the clinical blockade of IL-6 activity in autoimmunity, inflammation, and cancer.

Authors

Simon A. Jones, Jürgen Scheller, Stefan Rose-John

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2009 Total
Citations: 7 10 10 29 33 27 21 21 35 24 28 25 29 19 1 1 320
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2014 (25)

Title and authors Publication Year
Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis
TT Le, H Karmouty-Quintana, E Melicoff, TT Le, T Weng, NY Chen, M Pedroza, Y Zhou, J Davies, K Philip, J Molina, F Luo, AT George, LJ Garcia-Morales, RR Bunge, BA Bruckner, M Loebe, H Seethamraju, SK Agarwal, MR Blackburn
Journal of immunology (Baltimore, Md. : 1950) 2014
Alternative Intronic Polyadenylation Generates the Interleukin-6 Trans-signaling Inhibitor sgp130-E10
J Sommer, C Garbers, J Wolf, A Trad, JM Moll, M Sack, R Fischer, J Grotzinger, GH Waetzig, DM Floss, J Scheller
The Journal of biological chemistry 2014
Role of Ubiquitylation in Controlling Suppressor of Cytokine Signalling 3 (SOCS3) Function and Expression
J Williams, K Munro, T Palmer
Cells 2014
Interleukin-6 signaling drives fibrosis in unresolved inflammation
CA Fielding, GW Jones, RM McLoughlin, L McLeod, VJ Hammond, J Uceda, AS Williams, M Lambie, TL Foster, CT Liao, CM Rice, CJ Greenhill, CS Colmont, E Hams, B Coles, A Kift-Morgan, Z Newton, KJ Craig, JD Williams, GT Williams, SJ Davies, IR Humphreys, VB O'Donnell, PR Taylor, BJ Jenkins, N Topley, SA Jones
Immunity 2014
IL-6 as a Druggable Target in Psoriasis: Focus on Pustular Variants
A Saggini, S Chimenti, A Chiricozzi
Journal of Immunology Research 2014
Interleukins in chronic liver disease: lessons learned from experimental mouse models
L Hammerich, F Tacke
Clinical and experimental gastroenterology 2014
The different shades of fat
V Peirce, S Carobbio, A Vidal-Puig
Nature 2014
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
H Yu, H Lee, A Herrmann, R Buettner, R Jove
Nature Reviews Cancer 2014
Macrophage Polarization in Pancreatic Carcinoma: Role of Heparanase Enzyme
E Hermano, A Meirovitz, K Meir, G Nussbaum, L Appelbaum, T Peretz, M Elkin
JNCI Journal of the National Cancer Institute 2014
Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma
W Zhang, N Nandakumar, Y Shi, M Manzano, A Smith, G Graham, S Gupta, EE Vietsch, SZ Laughlin, M Wadhwa, M Chetram, M Joshi, F Wang, B Kallakury, J Toretsky, A Wellstein, C Yi
Science signaling 2014
Ectopic lymphoid-like structures in infection, cancer and autoimmunity
C Pitzalis, GW Jones, M Bombardieri, SA Jones
Nature Reviews Immunology 2014
Therapeutic effect of farnesylthiosalicylic acid on adjuvant-induced arthritis through suppressed release of inflammatory cytokines: FTS and arthritis
E Aizman, E Blacher, O Ben-Moshe, T Kogan, Y Kloog, A Mor
Clinical & Experimental Immunology 2014
Interleukin-6 Signaling, Soluble Glycoprotein 130, and Inflammation in Heart Failure
ET Askevold, L Gullestad, CP Dahl, A Yndestad, T Ueland, P Aukrust
Current Heart Failure Reports 2014
PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation
S Kolodziej, ON Kuvardina, T Oellerich, J Herglotz, I Backert, N Kohrs, E Buscató, SK Wittmann, G Salinas-Riester, H Bonig, M Karas, H Serve, E Proschak, J Lausen
Nature Communications 2014
Chemically modified DNA aptamers bind interleukin-6 with high affinity and inhibit signaling by blocking its interaction with interleukin-6 receptor
S Gupta, M Hirota, SM Waugh, I Murakami, T Suzuki, M Muraguchi, M Shibamori, Y Ishikawa, TC Jarvis, JD Carter, C Zhang, B Gawande, M Vrkljan, N Janjic, DJ Schneider
The Journal of biological chemistry 2014
IL-6 biology: implications for clinical targeting in rheumatic disease
LH Calabrese, S Rose-John
Nature Reviews Rheumatology 2014
Suppression of mucin 2 promotes interleukin-6 secretion and tumor growth in an orthotopic immune-competent colon cancer animal model
YS Shan, HP Hsu, MD Lai, MC Yen, JH Fang, TY Weng, YL Chen
Oncology reports 2014
Toll-like Receptor-Mediated Responses by Placental Hofbauer Cells (HBCs): A Potential Pro-Inflammatory Role for Fetal M2 Macrophages
OM Young, Z Tang, T Niven-Fairchild, S Tadesse, G Krikun, ER Norwitz, G Mor, VM Abrahams, S Guller
American Journal of Reproductive Immunology 2014
Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling
S Shaw, T Bourne, C Meier, B Carrington, R Gelinas, A Henry, A Popplewell, R Adams, T Baker, S Rapecki, D Marshall, A Moore, H Neale, A Lawson
mAbs 2014
Peripheral Nerve Regeneration and NGF-Dependent Neurite Outgrowth of Adult Sensory Neurons Converge on STAT3 Phosphorylation Downstream of Neuropoietic Cytokine Receptor gp130
S Quarta, BE Baeumer, N Scherbakov, M Andratsch, S Rose-John, G Dechant, CE Bandtlow, M Kress
The Journal of neuroscience : the official journal of the Society for Neuroscience 2014
A Disintegrin and Metalloprotease 17 Dynamic Interaction Sequence, the Sweet Tooth for the Human Interleukin 6 Receptor
S Düsterhöft, K Höbel, M Oldefest, J Lokau, GH Waetzig, A Chalaris, C Garbers, J Scheller, S Rose-John, I Lorenzen, J Grötzinger
The Journal of biological chemistry 2014
Pharmacologic Suppression of JAK1/2 by JAK1/2 Inhibitor AZD1480 Potently Inhibits IL-6-Induced Experimental Prostate Cancer Metastases Formation
L Gu, P Talati, P Vogiatzi, AL Romero-Weaver, J Abdulghani, Z Liao, B Leiby, DT Hoang, T Mirtti, K Alanen, M Zinda, D Huszar, MT Nevalainen
Molecular cancer therapeutics 2014
Control and consequences of IL-6 receptor ectodomain shedding
Scheller J
European Journal of Medical Research 2014
Clinical effects of soluble interleukin-6 receptor detection on autoimmune rheumatic disease patients
Chen M, Xu MH, Sun CX, Zhang Z, Du Y
Pakistan Journal of Medical Sciences 2014
Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation
Aparicio-Siegmund S, Sommer J, Monhasery N, Schwanbeck R, Keil E, Finkenstädt D, Pfeffer K, Rose-John S, Scheller J, Garbers C
Oncotarget 2014

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Posted by 1 X users
Referenced in 40 patents
Referenced in 1 Wikipedia pages
481 readers on Mendeley
1 readers on CiteULike
See more details